Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2017-07-12 M&A Activity
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
KOMPLETTERANDE INFORMATION TILL TIDIGARE PRESSMEDDELANDE IDAG
M&A Activity Classification · 99% confidence The document is a short press release (977 characters) dated July 12, 2017, announcing that Karo Pharma has acquired 100% of the shares in Medireduce AB for less than 5 MSEK. It explicitly states that the information is being made public according to the EU Market Abuse Regulation (MAR). Since this is a specific announcement regarding a corporate action (acquisition/merger) that is not a full report (like 10-K or IR) and doesn't fit perfectly into other categories like DIV, DIRS, or CAP (which usually implies financing/fundraising), it falls best under the general regulatory announcement category, RNS, as it is a mandatory disclosure under MAR. However, M&A Activity (TAR) is defined as 'Announcements and documents related to merger proposals or takeover bids.' An acquisition announcement fits this definition more specifically than the general RNS fallback. Given the content is a definitive announcement of a completed acquisition, TAR is the most appropriate specific code.
2017-07-12 Swedish
Annual General Meeting 2017 in Karo Pharma AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled 'Annual General Meeting 2017 in Karo Pharma AB (publ)' and details the resolutions passed at the AGM, including dividend approval, board member elections, and remuneration decisions. This content directly aligns with the definition of AGM Information. It is not a full 10-K, an earnings release, or a simple announcement of a report, but the summary of the meeting itself.
2017-05-11 English
Årsstämma 2017 i Karo Pharma AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Årsstämma 2017 i Karo Pharma AB (publ)" (Annual General Meeting 2017 in Karo Pharma AB (publ)) and details the key decisions made during that meeting, such as dividend approval, board member elections, and authorization for future share issues. This content directly corresponds to the definition of AGM Information. Although it is presented as a press release, the core subject matter is the outcome of the AGM, making AGM-R the most specific classification over a general Regulatory Filing (RNS). The document length is relatively short (2727 chars), but it reports the final decisions rather than announcing that a separate AGM document is available, thus it is not an RPA.
2017-05-11 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January to March 2017. It contains comprehensive financial statements, including the income statement, balance sheet, and cash flow analysis, as well as management commentary on business performance. It is not a mere announcement or certification, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). Q1 2017
2017-05-10 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY – MARCH 2017' and contains comprehensive financial statements, including the consolidated income statement, statement of comprehensive income, statement of financial position, and management commentary on operations, risks, and financial performance for the first quarter. It is not a mere announcement (RPA) as it provides full financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. Q1 2017
2017-05-10 English
Karo Pharma-Pfizer samarbetet når en andra milestone
Environmental & Social Information Classification · 99% confidence The document is a short press release dated May 4, 2017, announcing that Karo Pharma received a $2 million milestone payment from Pfizer for the RORgamma project. It includes quotes and contact information. The text explicitly states that the information is to be made public according to the EU Market Abuse Regulation ('EU:s marknadsmissbruksförordning'). This type of announcement, which is a specific, material event update but not a full financial report (like 10-K or IR) or a standard earnings release (ER), fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially a Capital/Financing Update (CAP) if the milestone is considered a financing event. Given the context of a specific, non-recurring event announcement mandated by market regulations, RNS is the most appropriate fallback for specific corporate actions not covered by other codes. It is too specific for a general ER and too short/event-driven for an IR or MDA. Since it is a direct announcement of a specific corporate event/payment, RNS is chosen as the best fit among the available options for non-standard regulatory disclosures.
2017-05-04 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.